<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">phkinetica</journal-id><journal-title-group><journal-title xml:lang="ru">Фармакокинетика и Фармакодинамика</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacokinetics and Pharmacodynamics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7836</issn><issn pub-type="epub">2686-8830</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/2587-7836-2025-4-112-117</article-id><article-id custom-type="elpub" pub-id-type="custom">phkinetica-492</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНОЕ ЭКСПЕРИМЕНТАЛЬНОЕ ИССЛЕДОВАНИЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL EXPERIMENTAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Влияние лигандов Sigma1R на судороги, вызванные блокадой ортостерического участка и хлорного канала ГАМК А-рецептора</article-title><trans-title-group xml:lang="en"><trans-title>Influence of Sigma1R ligands on seizures induced by blockade of the orthosteric site and chloride channel of the GABAA receptor</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1065-8899</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шангин</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shangin</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шангин Станислав Владимирович — м. н. с. лаборатории молекулярной фармакологии</p><p>Москва</p></bio><bio xml:lang="en"><p>Stanislav V. Shangin — Junior Researcher at the Laboratory of Molecular Pharmacology</p><p>Moscow</p></bio><email xlink:type="simple">shangin_sv@academpharm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7062-8261</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вахитова</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vakhitova</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вахитова Юлия Венеровна — д. б. н., член-корр. РАН ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России (Пироговский Университет)</p><p>Москва</p></bio><bio xml:lang="en"><p>Yulia V. Vakhitova — PhD, Dr. Sci. (Biology), RAS corresponding member, N.I. Pirogov Russian National Research Medical University</p><p>Moscow</p></bio><email xlink:type="simple">juvv73@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2477-0563</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Воронин</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Voronin</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Воронин Михаил Владимирович — д. м. н.</p><p>Москва</p></bio><bio xml:lang="en"><p>Mikhail V. Voronin — PhD, Dr. Sci. (Med.), Centre for Strategic Planning</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4482-9331</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Середенин</surname><given-names>С. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Seredenin</surname><given-names>S. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Середенин Сергей Борисович — д. м. н., профессор, академик РАН, ФГБУ «ЦСП» ФМБА России</p><p>Москва</p></bio><bio xml:lang="en"><p>Sergey B. Seredenin — PhD, Dr. Sci. (Med.), Professor, Academician of RAS, Centre for Strategic Planning, of the Federal medical and biological agency</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «ФИЦ оригинальных и перспективных биомедицинских и фармацевтических технологий»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal research center for innovator and emerging biomedical and pharmaceutical technologies</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУ «ЦСП» ФМБА России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Centre for Strategic Planning, of the Federal medical and biological agency</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2025</year></pub-date><volume>0</volume><issue>4</issue><fpage>112</fpage><lpage>117</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шангин С.В., Вахитова Ю.В., Воронин М.В., Середенин С.Б., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Шангин С.В., Вахитова Ю.В., Воронин М.В., Середенин С.Б.</copyright-holder><copyright-holder xml:lang="en">Shangin S.V., Vakhitova Y.V., Voronin M.V., Seredenin S.B.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacokinetica.ru/jour/article/view/492">https://www.pharmacokinetica.ru/jour/article/view/492</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Ранее была показана роль шаперона Sigma1R в модуляции эффектов аллостерических модуляторов ГАМКА-рецепторов, однако его влияние на процессы, связанные с ортостерическим сайтом связывания ГАМК и ионным каналом рецептора, остаётся малоизученным. При этом вопрос о вовлечённости Sigma1R в противосудорожный механизм действия агониста Sigma1R фабомотизола в условиях ингибирования ортостерического сайта связывания ГАМК или ионного канала рецептора остаётся открытым, несмотря на установленную Sigma1R-зависимость его эффекта в модели судорог, вызванных пентилентетразолом.</p></sec><sec><title>Цель работы</title><p>Цель работы. Оценить влияние лигандов Sigma1R PRE-084, BD-1047 и фабомотизола на пороги судорожных реакций в модели экспериментальных судорог у мышей, вызванных внутривенным введением пикротоксина и бикукуллина.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Исследование проводили на самцах мышей ICR. Судороги индуцировали внутривенной инфузией бикукуллина или пикротоксина. Фабомотизол (20 мг/кг), PRE-084 (10 и 20 мг/кг) и BD-1047 (10 и 20 мг/кг) вводили внутрибрюшинно за 90 минут до конвульсанта. Регистрировали пороговые дозы для возникновения клонических подергиваний, генерализованных клонических и тонических судорог.</p></sec><sec><title>Результаты</title><p>Результаты. Установлено противосудорожное действие фабомотизола в дозе 20 мг/кг, которое ослаблялось антагонистом Sigma1R шаперона BD-1047. Для селективного агониста Sigma1R шаперона PRE-084, также как и для антагониста BD-1047, собственных эффектов не зарегистрировано.</p></sec><sec><title>Заключение</title><p>Заключение. В результате проведённого исследования установлено, что противосудорожное действие фабомотизола на моделях бикукуллин и пикротоксин-индуцированных судорог опосредовано активацией Sigma1R. Отличие фармакологического действия фабомотизола от эффектов классического агониста PRE-084 указывает на возможность существования дополнительных, пока не изученных механизмов взаимодействия Sigma1R с ГАМКА-рецептором, что открывает новые направления для дальнейших исследований.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Relevance</title><p>Relevance. The role of the Sigma1R chaperone in modulating the eﬀects of allosteric modulators of GABAA receptors has been previously demonstrated.</p><p>However, its inﬂuence on processes associated with the orthosteric GABA-binding site and the chloride channel of the receptor remains poorly understood. Despite the established Sigma1R-dependent eﬀect of fabomotizole in the pentylenetetrazole-induced seizure model, the involvement of Sigma1R in its anticonvulsant mechanism under conditions of orthosteric GABA-binding site or chloride channel inhibition remains unclear.</p></sec><sec><title>Objective</title><p>Objective. To evaluate the inﬂuence of Sigma1R ligands PRE-084, BD-1047, and fabomotizole on seizure thresholds in mouse models of seizures induced by intravenous administration of bicuculline and picrotoxin.</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods. The study was conducted on male ICR mice. Seizures were induced by intravenous infusion of bicuculline or picrotoxin. Fabomotizole (20 mg/kg), PRE-084 (10 and 20 mg/kg), and BD-1047 (10 and 20 mg/kg) were administered intraperitoneally 90 minutes prior to the convulsant. Threshold doses for the onset of clonic jerks, generalized clonic, and tonic seizures were recorded.</p></sec><sec><title>Results</title><p>Results. An anticonvulsant eﬀect of fabomotizole at a dose of 20 mg/kg was demonstrated, which was attenuated by the Sigma1R chaperone antagonist BD-1047. No intrinsic eﬀects were observed for either the selective Sigma1R agonist PRE-084 or the antagonist BD-1047.</p></sec><sec><title>Conclusion</title><p>Conclusion. The present study demonstrated that the anticonvulsant action of fabomotizole in bicuculline- and picrotoxin-induced seizure models is mediated by Sigma1R activation. The diﬀerence between the pharmacological action of fabomotizole and that of the classical agonist PRE-084 suggests the existence of additional, as yet unstudied, mechanisms of Sigma1R interaction with the GABAA receptor, which opens new avenues for further research.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ГАМК А -рецепторы</kwd><kwd>фабомотизол</kwd><kwd>бикукуллин</kwd><kwd>пикротоксин</kwd><kwd>судороги</kwd><kwd>шаперон Sigma1R</kwd><kwd>BD 1047</kwd><kwd>PRE-084</kwd></kwd-group><kwd-group xml:lang="en"><kwd>GABA A receptors</kwd><kwd>fabomotizole</kwd><kwd>bicuculline</kwd><kwd>picrotoxin</kwd><kwd>seizures</kwd><kwd>Sigma1R chaperone</kwd><kwd>BD-1047</kwd><kwd>PRE-084</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках государственного задания Министерства науки и высшего образования Российской Федерации № FGFG-2025-0004.</funding-statement><funding-statement xml:lang="en">This work was conducted under the government contracts of the Ministry of Science and Higher Education of the Russian Federation (Project FGFG- 2025-0004).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Voronin MV, Shangin SV, Litvinova SA, et al. Pharmacological Analysis of GABAA Receptor and Sigma1R Chaperone Interaction: Research Report I-Investigation of the Anxiolytic, Anticonvulsant and Hypnotic Effects of Allosteric GABAA Receptors' Ligands. Int J Mol Sci. 2023 May 31;24(11):9580. doi: 10.3390/ijms24119580.</mixed-citation><mixed-citation xml:lang="en">Voronin MV, Shangin SV, Litvinova SA, et al. Pharmacological Analysis of GABAA Receptor and Sigma1R Chaperone Interaction: Research Report I-Investigation of the Anxiolytic, Anticonvulsant and Hypnotic Effects of Allosteric GABAA Receptors' Ligands. Int J Mol Sci. 2023 May 31;24(11):9580. doi: 10.3390/ijms24119580.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Vavers E, Svalbe B, Lauberte L, et al. The activity of selective sigma-1 receptor ligands in seizure models in vivo. Behav Brain Res. 2017 Jun 15;328:13-18. doi: 10.1016/j.bbr.2017.04.008.</mixed-citation><mixed-citation xml:lang="en">Vavers E, Svalbe B, Lauberte L, et al. The activity of selective sigma-1 receptor ligands in seizure models in vivo. Behav Brain Res. 2017 Jun 15;328:13-18. doi: 10.1016/j.bbr.2017.04.008.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Voronin MV, Vakhitova YV, Tsypysheva IP, et al. Involvement of Chaperone Sigma1R in the Anxiolytic Effect of Fabomotizole. Int J Mol Sci. 2021 May 21;22(11):5455. doi: 10.3390/ijms22115455.</mixed-citation><mixed-citation xml:lang="en">Voronin MV, Vakhitova YV, Tsypysheva IP, et al. Involvement of Chaperone Sigma1R in the Anxiolytic Effect of Fabomotizole. Int J Mol Sci. 2021 May 21;22(11):5455. doi: 10.3390/ijms22115455.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Shangin SV, Vakhitova YV, Litvinova SA, et al. Anticonvulsant Properties of Fabomotizole When Administered Separately and in Conjunction with Diazepam. Pharmaceutical Chemistry Journal. 2025;59(7):711-716. doi: 10.1007/s11094-025-03445-6.</mixed-citation><mixed-citation xml:lang="en">Shangin SV, Vakhitova YV, Litvinova SA, et al. Anticonvulsant Properties of Fabomotizole When Administered Separately and in Conjunction with Diazepam. Pharmaceutical Chemistry Journal. 2025;59(7):711-716. doi: 10.1007/s11094-025-03445-6.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Vavers E, Zvejniece B, Stelfa G, et al. Genetic inactivation of the sigma-1 chaperone protein results in decreased expression of the R2 subunit of the GABA-B receptor and increased susceptibility to seizures. Neurobiol Dis. 2021 Mar;150:105244. doi: 10.1016/j.nbd.2020.105244.</mixed-citation><mixed-citation xml:lang="en">Vavers E, Zvejniece B, Stelfa G, et al. Genetic inactivation of the sigma-1 chaperone protein results in decreased expression of the R2 subunit of the GABA-B receptor and increased susceptibility to seizures. Neurobiol Dis. 2021 Mar;150:105244. doi: 10.1016/j.nbd.2020.105244.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Martin P, Reeder T, Sourbron J, et al. An Emerging Role for Sigma-1 Receptors in the Treatment of Developmental and Epileptic Encephalopathies. Int J Mol Sci. 2021 Aug 5;22(16):8416.</mixed-citation><mixed-citation xml:lang="en">Martin P, Reeder T, Sourbron J, et al. An Emerging Role for Sigma-1 Receptors in the Treatment of Developmental and Epileptic Encephalopathies. Int J Mol Sci. 2021 Aug 5;22(16):8416.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Johnston GA. Advantages of an antagonist: bicuculline and other GABA antagonists. Br J Pharmacol. 2013 May;169(2):328-36. doi: 10.1111/bph.12127.</mixed-citation><mixed-citation xml:lang="en">Johnston GA. Advantages of an antagonist: bicuculline and other GABA antagonists. Br J Pharmacol. 2013 May;169(2):328-36. doi: 10.1111/bph.12127.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Chen L, Durkin KA, Casida JE. Structural model for gammaaminobutyric acid receptor noncompetitive antagonist binding: widely diverse structures fit the same site. Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5185-90. doi: 10.1073/pnas.0600370103.</mixed-citation><mixed-citation xml:lang="en">Chen L, Durkin KA, Casida JE. Structural model for gammaaminobutyric acid receptor noncompetitive antagonist binding: widely diverse structures fit the same site. Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5185-90. doi: 10.1073/pnas.0600370103.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Шангин С. В., Мариевский В. Е., Вахитова Ю. В. Оптимизация условий экспериментальных моделей, опосредованных нарушением ГАМК-ергической нейропередачи. Фармакокинетика и фармакодинамика. 2025;(4). (в печати).</mixed-citation><mixed-citation xml:lang="en">Shangin SV, Marievskii VE, Vakhitova YV. The optimization of experimental models mediated by impaired gabaergic neurotransmission. Farmakokinetika i farmakodinamika = Pharmacokinetics and pharmacodynamics. 2025;(4). (in press). (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Jamali H, Heydari A. Effect of dextromethorphan/quinidine on pentylenetetrazole- induced clonic and tonic seizure thresholds in mice. Neurosci Lett. 2020 Jun 11;729:134988. doi: 10.1016/j.neulet.2020.134988.</mixed-citation><mixed-citation xml:lang="en">Jamali H, Heydari A. Effect of dextromethorphan/quinidine on pentylenetetrazole- induced clonic and tonic seizure thresholds in mice. Neurosci Lett. 2020 Jun 11;729:134988. doi: 10.1016/j.neulet.2020.134988.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Shin EJ, Nah SY, Kim WK, et al. The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan. Br J Pharmacol. 2005 Apr;144(7):908-18. doi: 10.1038/sj.bjp.0705998.</mixed-citation><mixed-citation xml:lang="en">Shin EJ, Nah SY, Kim WK, et al. The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan. Br J Pharmacol. 2005 Apr;144(7):908-18. doi: 10.1038/sj.bjp.0705998.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Vavers E, Zvejniece L, Dambrova M. Sigma-1 receptor and seizures. Pharmacol Res. 2023 May;191:106771. doi: 10.1016/j.phrs.2023.106771.</mixed-citation><mixed-citation xml:lang="en">Vavers E, Zvejniece L, Dambrova M. Sigma-1 receptor and seizures. Pharmacol Res. 2023 May;191:106771. doi: 10.1016/j.phrs.2023.106771.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Akaike N, Hattori K, Oomura Y, Carpenter DO. Bicuculline and picrotoxin block gamma-aminobutyric acid-gated Cl- conductance by different mechanisms. Experientia. 1985 Jan 15;41(1):70-1. doi: 10.1007/BF02005880.</mixed-citation><mixed-citation xml:lang="en">Akaike N, Hattori K, Oomura Y, Carpenter DO. Bicuculline and picrotoxin block gamma-aminobutyric acid-gated Cl- conductance by different mechanisms. Experientia. 1985 Jan 15;41(1):70-1. doi: 10.1007/BF02005880.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia. 2001;42 Suppl 3:8-12. doi: 10.1046/j.1528-1157.2001.042suppl.3008.x.</mixed-citation><mixed-citation xml:lang="en">Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia. 2001;42 Suppl 3:8-12. doi: 10.1046/j.1528-1157.2001.042suppl.3008.x.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Raimondo JV, Burman RJ, Katz AA, Akerman CJ. Ion dynamics during seizures. Front Cell Neurosci. 2015 Oct 21;9:419. doi: 10.3389/fncel.2015.00419.</mixed-citation><mixed-citation xml:lang="en">Raimondo JV, Burman RJ, Katz AA, Akerman CJ. Ion dynamics during seizures. Front Cell Neurosci. 2015 Oct 21;9:419. doi: 10.3389/fncel.2015.00419.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
